Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.62 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL11052847 | 0.95 | CYP3A4 (0.57) | CYP3A4SLC7A5LTA4HNLN | |
| SCHEMBL28129417 | 0.83 | CYP3A4 (0.51) | CYP3A4SLC7A5 | |
| SCHEMBL13061496 | 0.83 | LTA4H (0.62) | CYP3A4SLC7A5LTA4HNLN | |
| SCHEMBL1007042 | 0.83 | CYP3A4 (0.61) | CYP3A4SLC7A5LTA4HNLN | |
| SCHEMBL713213 | 0.83 | LTA4H (0.62) | CYP3A4SLC7A5LTA4HNLN | |
| SCHEMBL388562 | 0.82 | CYP3A4 (0.73) | CYP3A4SLC7A5 | |
| SCHEMBL27557588 | 0.82 | LTA4H (0.56) | CYP3A4SLC7A5LTA4HNLN | |
| Hydrochloric Acid SCHEMBL27320108 | 0.82 | LTA4H (0.61) | CYP3A4SLC7A5LTA4H | |
| SCHEMBL27991996 | 0.81 | CYP3A4 (0.52) | CYP3A4SLC7A5LTA4HNLN | |
| SCHEMBL163444 | 0.81 | CYP3A4 (0.71) | CYP3A4SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117425495-A | Combination for the treatment of cancer | 赛达克斯制药股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-109748874-A | A kind of preparation method of anserine and its intermediate | 南京纽邦生物科技有限公司 | 2019-05-14 | — | — | CN | disclosed |
| CN-109748875-A | A kind of preparation method of whale carnosine and its intermediate | 南京纽邦生物科技有限公司 | 2019-05-14 | — | — | CN | disclosed |
| CN-106103480-A | For interleukin-13 3(IL 33) antibody | 安奈普泰斯生物有限公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-105120887-A | Growth hormone compound formulation | NOVO NORDISK HEALTHCARE AG | 2015-12-02 | — | — | CN | disclosed |
| EP-2811999-A1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2014-12-17 | — | — | EP | disclosed |
| WO-2013116663-A1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-08-08 | — | — | WO | disclosed |
| US-8372871-B2 | Histidinol dehydrogenase inhibitors, and use thereof as medicaments | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-02-12 | — | — | US | disclosed |
| US-20120129907-A1 | HISTIDINOL DEHYDROGENASE INHIBITORS, AND USE THEREOF AS MEDICAMENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-05-24 | — | — | US | disclosed |
| CN-100591649-C | Method of preparing R-(+)-3-chlorophenylpropanol | TIANDU CHEN | 2010-02-24 | — | — | CN | disclosed |
| CN-101012147-A | Method of preparing R-(+)-3-chlorophenylpropanol | CHEN TIANDU (CN) | 2007-08-08 | — | — | CN | disclosed |
| EP-1135398-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | Monsanto Technology LLC (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6218563-B1 | Cyanophosphonamides and method for preparation | MONSANTO COMPANY | 2001-04-17 | — | — | US | disclosed |
| WO-2000032611-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | MONSANTO TECHNOLOGY LLC (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129907-A1 | HISTIDINOL DEHYDROGENASE INHIBITORS, AND USE THEREOF AS MEDICAMENTS | MDH2, MDH1, G6PD | CYP3A4 696/4885SLC7A5 1006/4885LTA4H 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.